1. Home
  2. KTTA vs IDAI Comparison

KTTA vs IDAI Comparison

Compare KTTA & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

N/A

Current Price

$0.38

Market Cap

15.6M

Sector

Health Care

ML Signal

N/A

Logo T Stamp Inc.

IDAI

T Stamp Inc.

N/A

Current Price

$2.84

Market Cap

15.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
IDAI
Founded
2020
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
15.9M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
KTTA
IDAI
Price
$0.38
$2.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 282.6K
44.2K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 77.07
76.50
EPS
★ N/A
N/A
Revenue
★ $486,559.00
N/A
Revenue This Year
N/A
$59.48
Revenue Next Year
N/A
$199.81
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 3130.37
N/A
52 Week Low
$0.28
$1.17
52 Week High
$2.06
$5.28

Technical Indicators

Market Signals
Indicator
KTTA
IDAI
Relative Strength Index (RSI) 33.69 48.14
Support Level $0.36 $2.79
Resistance Level $0.52 $3.53
Average True Range (ATR) 0.05 0.28
MACD -0.00 -0.00
Stochastic Oscillator 14.56 64.94

Price Performance

Historical Comparison
KTTA
IDAI

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.

Share on Social Networks: